Skip to content
Menu

Unicycive Therapeutics, Inc. UNCY

Full chart Compare
Set alert

Price alert · UNCY

All alert types
3.53 USD -0.04 (-1.12%)

Regular-session close

3.53 0.00 +0.07%

After hours · Nov 19, 7:58 PM ET

3.42 Day range 3.65
3.33 52-week range 8.74
YTD
-38.82%
1 year
-36.17%

5D -0.11 (-3.03%)

3.603.80FriMonTueWedThu3.52
Market cap
103.02M
EPS (ttm)
-1.64
Shares out
103.80M
Forward P/E
-3.31
YTD return
-38.82%
1-year return
-36.17%
50-day average
0.55888
200-day average
0.700475
Volume
855.18K
Avg volume
954.65K
Open
3.57
Previous close
3.57
Day's range
3.42 – 3.65
52-week range
3.33 – 8.74
Beta
2.29
Price target
5.50 (+55.8%)

Key statistics

Enterprise value
47.31M
Free cash flow
-16.69M
Total cash
41.78M
Total debt
634.00K
Return on equity
-121.76%
Short % of float
1.21%

Fundamental scorecard

5 of 25 checks passed on UNCY’s reported financials

ValueGrowthProfitabilityHealthDividend

5of 25 checks passed

  • Value 1 of 5
  • Growth 1 of 5
  • Profitability 0 of 5
  • Financial health 3 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
UNCY Revenue — quarterly 0
UNCY Net income — quarterly -7.00M
UNCY EPS — quarterly -0.25

Earnings

UNCY recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 13, 2024Sep 1, 2024-0.13-0.05+0.08+61.54%
Aug 14, 2024Jun 1, 2024-0.23———
Aug 14, 2024Jun 1, 2024-0.23-0.15+0.08+34.78%
May 13, 2024Mar 1, 2024-0.18———
May 13, 2024Mar 1, 2024-0.18-0.27-0.09-50.00%
Mar 28, 2024Dec 1, 2023-0.18-0.16+0.02+11.11%

Upgrades / downgrades

UNCY analyst upgrades and downgrades
DateFirmActionFromTo
Nov 22, 2024BenchmarkreitSpeculative BuySpeculative Buy
Nov 14, 2024HC Wainwright & Co.mainBuyBuy
Nov 12, 2024HC Wainwright & Co.reitBuyBuy
Oct 9, 2024HC Wainwright & Co.reitBuyBuy
Sep 6, 2024BenchmarkreitSpeculative BuySpeculative Buy
Sep 3, 2024HC Wainwright & Co.reitBuyBuy

About Unicycive Therapeutics, Inc.

Unicycive Therapeutics, Inc., a biotechnology company, develops treatments for various medical conditions in the United States. Its drug candidates include UNI 494, a pro-drug of Nicorandil that is being developed as a treatment for acute kidney injury; and Renazorb (Oxylanthanum Carbonate), which is being developed for the treatment of hyperphosphatemia in patients with chronic kidney disease. Unicycive Therapeutics, Inc. has license agreements with Shilpa Medicare Ltd; Sphaera Pharma Pte. Ltd.; Syneos Health LLC; Inotiv; Lee's Pharmaceutical (HK) Limited; Celerion; and Lotus International Pte Ltd. The company was incorporated in 2016 and is based in Los Altos, California.

Sector
Healthcare
Industry
Biotechnology
Country
United States

News

Your note

Sign in to keep a note on UNCY — it syncs with the Stock Master app.

Insider holders

UNCY insider holders
InsiderRelationLatest transactionDateShares held
AGGARWAL GAURAVDirectorConversion of Exercise of derivative securityOct 8, 20240
GUPTA PRAMODOfficerConversion of Exercise of derivative securityJul 10, 202341,845
GUPTA SHALABH KChief Executive OfficerConversion of Exercise of derivative securityJul 10, 20232,527,450
JERMASEK DOUGLASOfficerConversion of Exercise of derivative securityJul 10, 2023175,012

Institution ownership

UNCY institution ownership
Holder% heldSharesValueReported
Great Point Partners LLC8.25%8,559,0005.67MSep 29, 2024
Octagon Capital Advisors LP8.25%8,559,0005.67MSep 29, 2024
Logos Global Management LP4.89%5,078,9273.37MSep 29, 2024
Walleye Capital LLC4.82%5,000,0003.31MSep 29, 2024
Vivo Capital, LLC4.31%4,470,1522.96MSep 29, 2024
SilverArc Capital Management, LLC3.85%4,000,0002.65MSep 29, 2024

Fund ownership

UNCY fund ownership
Holder% heldSharesValueReported
Vanguard Total Stock Market Index Fund0.74%765,000507.19KSep 29, 2024
Vanguard Extended Market Index Fund0.36%373,220247.44KSep 29, 2024
Fidelity Extended Market Index Fund0.22%229,420152.10KOct 30, 2024
Fidelity Total Market Index Fund0.07%71,48847.40KOct 30, 2024
iShares Micro Cap ETF0.06%65,36643.34KOct 30, 2024
Fidelity Series Total Market Index Fund0.05%54,03235.82KOct 30, 2024